Ixazomib + Pomalidomide + Dexamethasone In MM

Paul G. Richardson, MD (Other)
Overall Status
CT.gov ID
Takeda (Industry)
Anticipated Duration (Months)
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a Phase I/II study using the combination of twice weekly ixazomib plus pomalidomide and dexamethasone in relapsed and or refractory multiple myeloma (RRMM) patients.

Detailed Description

This is a Phase I/II clinical trial. A Phase I clinical trial tests the safety of an investigational drug and tries to define the appropriate dose of the investigational drug to use for further studies. "Investigational" means that the drug is being studied.

The FDA has approved both pomalidomide and ixazomib individually for the treatment of multiple myeloma. Dexamethasone, also FDA approved, is a type of steroid and is usually combined with other chemotherapy for the treatment of blood cancers, such as myeloma and leukemias.

  • Ixazomib targets a part of cells called proteasomes. It works by slowing down or blocking proteasomes from doing their job of digesting proteins. In myeloma cells, there is a greater need for proteasomes to digest proteins; the buildup of excess proteins causes cell death.

  • Pomalidomide has also been shown to cause tumor cell deaths. Dexamethasone can stop white blood cells from traveling to areas myeloma cells are causing damage. When combined with myeloma drugs, it sometimes makes those drugs work better.

In this research study, the investigators are:
  • Testing the safety of ixazomib when given with pomalidomide and dexamethasone

  • Pomalidomide and ixazomib are given individually for the treatment of multiple myeloma. Dexamethasone is also given for multiple myeloma

  • Ixazomib when combined with pomalidomide and dexamethasone may help control the disease

  • Ixazomib is FDA approved to treat multiple myeloma

  • The investigators are looking for the highest dose of ixazomib that can be given safely in combination with pomalidomide and dexamethasone

Study Design

Study Type:
Anticipated Enrollment :
61 participants
Intervention Model:
Single Group Assignment
None (Open Label)
Primary Purpose:
Official Title:
Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed/or Refractory Multiple Myeloma
Actual Study Start Date :
Sep 18, 2019
Anticipated Primary Completion Date :
Mar 20, 2022
Anticipated Study Completion Date :
Mar 20, 2022

Arms and Interventions

Experimental: ixazomib plus pomalidomide and dexamethasone

The study drugs will be administered within a 21-day cycle Phase I will follow a standard "3 +3" dose escalation design: Starting with the first cohort, 3 to 6 patients will be treated at this and each subsequent dose level. The Phase II portion of the study will be a single-arm open-label enrollment with dosing based on the MTD determination in the Phase I portion of the study

Drug: Ixazomib
Oral, administered four times per cycle
Other Names:
  • Ninlaro®
  • Drug: Pomalidomide
    Oral, administered 14 times per cycle
    Other Names:
  • Pomalyst®
  • Drug: Dexamethasone
    Oral, fixed dose administered 8 times per cycle
    Other Names:
  • Baycadron
  • Decadron
  • Dexamethasone Intensol
  • DexPak
  • TaperDex
  • Zema-Pak
  • ZoDex
  • Zonacort
  • Outcome Measures

    Primary Outcome Measures

    1. Number of participants with dose limiting toxicity [21 Days]

      3 - 24 safety evaluable patients will be enrolled in up to 4 dose levels of ixazomib, pomalidomide and dexamethasone.

    2. Overall Response Rate [28 days]

      Response will be evaluated using a Simon optimal two-stage design

    Secondary Outcome Measures

    1. Time to Progression [time from first dose of study drug to progression, censored at date last known progression-free for those who have not progressed, whichever came first, assessed up to 60 months]

      Estimated using the method of Kaplan-Meier.

    2. Progression Free Survival [time from first dose of study drug to the disease progression or death from any cause, censored at date last known progression-free for those who have not progressed or died, whichever came first, assessed up to 60 months]

      Estimated using the method of Kaplan-Meier.

    3. Duration of Response [time from response to disease progression or death, or date last known progression-free and alive for those who have not progressed or died, whichever came first, assessed up to 60 months]

      Estimated using the method of Kaplan-Meier.

    4. Overall Survival [time from first dose of study drug to death or date last known alive, whichever came first, assessed up to 60 months]

      Estimated using the method of Kaplan-Meier.

    Eligibility Criteria


    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Accepts Healthy Volunteers:
    Inclusion Criteria:
    • Patients with relapsed and relapsed refractory myeloma may be eligible for this trial of they meet all the following entry criteria.

    • Previously diagnosed with MM based on standard IMWG criteria and currently requires treatment.

    • Patient has given voluntary written informed consent before performance of any study-related procedures not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care

    • Patient had received at least two previous therapies OR received 1 prior line of therapy if previously treated with an IMiD plus a proteasome inhibitor and has demonstrated disease progression on or within 60 days of completion of the last therapy

    • Patient has measurable disease defined as at least one of the following according to

    Standard Diagnostic Criteria (Rajkumar 2014):
    • Serum IgG, IgA, or IgM M-protein ≥ 0.5 g/dL, or

    • Serum IgD M-protein ≥ 0.05 g/dL, or

    • Urine M protein ≥200 mg/24 hours or

    • Serum free light chain (FLC) assay: Involved FLC assay ≥10 mg/dL (≥100 mg/L) and an abnormal serum FLC ratio (<0.26 or >1.65)

    • Screening Laboratory evaluations within the following parameters

    • Absolute neutrophil count (ANC) ≥ 1,000 cells/dL (1.0 x 109/L) (Growth factors cannot be used more recently than 14 days prior to initiation of therapy)

    • Platelet count ≥ 75,000 cells/dL (75 x 109/L) (without transfusions required during the 14 days prior to initiation of therapy)

    • Hemoglobin ≥ 8.0 g/dl (RBC transfusions are permitted)

    • Total Bilirubin ≤ 1.5 X upper limit of normal (ULN) (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)

    • AST (SGOT) and ALT (SGPT) ≤ 3.0 x ULN

    • Calculated creatinine clearance ≥ 45 mL/min

    • ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)

    • All study participants must be registered into the mandatory POMALYST REMS® program, and be willing and able to comply with the requirements of the POMALYST REMS® program.

    • Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the POMALYST REMS® program.

    • Ability to understand and the willingness to sign a written informed consent document.

    Exclusion Criteria:
    • Prior exposure to ixazomib OR is refractory to pomalidomide

    • Patients that have previously been treated with ixazomib, or participated in a study with ixazomib,whether treated with the agent or not, are also excluded

    • Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial.

    • Diagnosed or treated for another malignancy within 3 years prior to enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low risk prostate cancer after curative therapy.

    • Known GI disease or is in need of, or has had a previous GI procedure that could interfere with the oral absorption or tolerance of ixazomib or pomalidomide including difficulty swallowing.

    • Known central nervous system involvement.

    • Systemic treatment, within 14 days before the first dose of treatment, with strong CYP3A or inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of St. John's wort OR systemic treatment within 14 days of the first dose of treatment with a strong inhibitor of CYP1A2 (ciprofloxacin, fluvoxamine, cimetidine, enoxacin, ethynyl estradiol, mexiletine)

    • Any medical or psychiatric illness/social situation that in the Investigator's opinion, would impose excessive risk to the patient, would adversely affect his/her participating in this study or would limit compliance with study requirements.

    • Any active, or uncontrolled cardiovascular conditions, including but not limited to uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, grade 3 thromboembolic event or myocardial infarction within the past 6 months.

    • The following therapies within the stated time frames prior to initiation of therapy:

    • Previous cytotoxic therapies, including cytotoxic investigational agents, for multiple myeloma within 21 days (42 days for nitrosoureas).

    • The use of live vaccines within 30 days.

    • ImiDs or proteasome inhibitors within 14 days.

    • Other investigational therapies and/or monoclonal antibodies within 4 weeks.

    • Prior peripheral stem cell transplant within 12 weeks.

    • Prior allogeneic stem cell transplantation with active graft-versus-host-disease.

    • Currently active graft versus host disease of any stage or grade after allogeneic stem cell transplantation

    • Prior major surgical procedure or radiation therapy within 14 days of initiation of therapy.

    • Those who require a limited course of radiation for management of bone pain more than 14 days out from initiation of therapy are not excluded

    • If the involved field is small, 7 days will be considered a sufficient interval between radiotherapy and administration of the ixazomib.

    • Daily requirement for corticosteroids (equivalent to > 10 mg/day prednisone, though

    10mg/day is acceptable if physiological levels require, so long as the dose is stable for at least 7 days prior to initiation of therapy. Inhalation corticosteroids are exempt from this criterion.

    -- Lower amounts of corticosteroids that are not part of a daily requirement within 14 days prior to initiating therapy

    • Concurrent symptomatic amyloidosis or plasma cell leukemia

    • POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes)

    • Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment.

    -- Those who are on prophylactic antibiotics only, or on antibiotics and have confirmation of resolution of active infection are eligible.

    • Known seropositive for active viral infection with human immunodeficiency virus (HIV) hepatitis B (HBV) or hepatitis C viral (HCV). Those who are seropositive because of hepatitis B vaccine are eligible. Patients who are positive for HBV core antibody or HBV surface antigen must have a negative polymerase chain reaction (PCR) result prior to enrollment. Those who are PCR positive will be excluded

    • Female patients who are lactating or have a positive serum pregnancy test during the screening period

    • Participants who are receiving any other investigational agents for any indication

    • History of erythema multiforme or severe hypersensitivity to prior IMiD's® or those who have a known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.

    • Inability to tolerate thromboprophylaxis

    • Failure to have fully recovered (≤ Grade 1 according to CTCAE v 5) from the reversible effects of prior chemotherapy

    • Peripheral neuropathy must have resolved to Grade 1 toxicity or peripheral neuropathy grade 2 with no pain to be eligible

    • Alopecia of any grade is eligible

    Contacts and Locations


    SiteCityStateCountryPostal Code
    1Dana Farber Cancer InstituteBostonMassachusettsUnited States02115

    Sponsors and Collaborators

    • Paul G. Richardson, MD
    • Takeda


    • Principal Investigator: Paul Richardson, MD, Dana-Farber Cancer Institute

    Study Documents (Full-Text)

    None provided.

    More Information


    None provided.
    Responsible Party:
    Paul G. Richardson, MD, Principal Investigator, Dana-Farber Cancer Institute
    ClinicalTrials.gov Identifier:
    Other Study ID Numbers:
    • 19-291
    First Posted:
    Sep 19, 2019
    Last Update Posted:
    Feb 18, 2021
    Last Verified:
    Feb 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Plan to Share IPD:
    Studies a U.S. FDA-regulated Drug Product:
    Studies a U.S. FDA-regulated Device Product:
    Keywords provided by Paul G. Richardson, MD, Principal Investigator, Dana-Farber Cancer Institute
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 18, 2021